Combined General Meeting of June 24, 2024
Combined General Meeting of June 24, 2024
Shareholders are strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via the secure online platform VOTACCESS.PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université - Amphi Herpin - 4 Place Jussieu, 75005 Paris.
2024年6月7日，法国巴黎和美国马萨诸塞州剑桥/ACCESSWIRE/——临床阶段生物技术公司Biophytis SA (Euronext Growth Paris:ALBPS), (“Biophytis”或“公司”)，专注于治疗与年龄相关的疾病的治疗方案的开发，将于2024年6月24日下午2点在Paris 75005 Jussieu 4号 Herpin讲堂举办其联合大会(CGM)。
The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO) no. 59 of May 15, 2024.
会议通知，包括议程、草案决议和出席的条款和条件，已发布在2024年5月15日的Bulletin des Annonces Légales Obligatoires (BALO)第59号中。
Information and preparatory documents for this General Meeting, including the voting form and the access map, are available on the Company's website ().
本次股东大会的相关信息和准备文件，包括投票表和进入地图，都可在公司网站上 ().
Shareholders are strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via the secure online platform VOTACCESS.
强烈鼓励股东提前参与投票，通过邮寄 (i)、指定会议主席为代理人 (ii)，或通过安全的在线平台 VOTACCESS 投票(iii) 参与 CGM。代理投票或者邮寄投票需在股东大会前三天提交 (即 2024 年 6 月 21 日前) 在线投票需在股东大会前一天提交 (即 2024 年 6 月 23 日前)。
Votes must be submitted no later than three days before the general meeting (i.e. June 21, 2024) for proxy votes or postal votes and the day before for proxy votes or postal votes via VOTACCESS (i.e. June 23, 2024).
强烈鼓励股东提前参与投票，通过邮寄 (i)、指定会议主席为代理人 (ii)，或通过安全的在线平台 VOTACCESS 投票(iii) 参与 CGM。代理投票或者邮寄投票需在股东大会前三天提交 (即 2024 年 6 月 21 日前) 在线投票需在股东大会前一天提交 (即 2024 年 6 月 23 日前)。
****
****
About BIOPHYTIS
关于Biophytis
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The Company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on OTC market (Ticker: BPTSY - ISIN: US09076G4010). For more information, visit
Biophytis SA 是一家专门从事研发老年相关疾病药物候选品的临床阶段生物技术公司。 BIO101（20-羟基蜕皮激素）是我们的主要药物候选品，是一种小分子化合物，正在开发针对肌肉（肌肉萎缩症，阶段3待就绪和杜兴氏肌营养不良），呼吸系统（Covid-19阶段2-3已完成）和代谢疾病（肥胖症，阶段2即将开始）的治疗方案。公司总部设在法国巴黎和马萨诸塞州剑桥市。公司的普通股票上市交易于欧洲纳斯达克(Euronext Growth)上（代码: ALBPS - ISIN: FR0012816825），美国存托股曾上市于OTC市场 (代码:BPTSY - ISIN: US09076G4010)。欲了解更多信息，请访问
Forward-looking statements
前瞻性声明 本新闻稿中包括的关于未来表现和结果、预期、规划、策略、重点、承诺和其他声明（包括与我们社会、环境和其他可持续性目标有关的声明）的非历史事实的前瞻性声明，是根据美国联邦证券法的定义而作出的前瞻性声明。本新闻稿中关于我们环境和其他可持续性计划和目标的前瞻性声明以及其他声明并不意味着这些声明对于投资者、我们的业务、运营结果、财务状况、前景或策略、对我们在可持续发展事项上的影响或其他当事方来说均是重要的，或者必须披露在我们向证券交易委员会（“SEC”）或其他监管机构的备案中。此外，历史、现有及未来涉及社会、环境和可持续性的相关声明可能是基于仍在发展的衡量进展的标准、不断演变的内部控制和流程以及假设，在将来可能会发生变化。前瞻性声明基于当前的信仰、期望和假设，并受到可能导致实际结果与前瞻性声明有实质性差异的重大风险、不确定性和情况变化的影响。
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
本新闻稿包含前瞻性声明。前瞻性声明包括所有非历史事实陈述。 在某些情况下，您可以通过使用“前景展望”，“相信”，“期望”，“潜力”，“继续，”，“可能”，“将” ，“应该”，“可能”，“寻求”，“预测”，“打算”，“趋势”，“计划”，“估计”，“预计” 或这些词的负面版本或其他可比较的词语来识别这些前瞻性陈述。 这类前瞻性声明是基于Biophytis认为合理的假设。然而，不能保证这些前瞻性陈述中包含的陈述将得到证实，这些陈述还可能受到各种风险和不确定性的影响。此 新闻稿中包含的前瞻性声明也可能受到 Biophytis 尚未了解或目前不认为重要的风险的影响。因此，存在或将存在重要因素可能导致实际结果或成果与这些声明中指示的结果存在重大差异。此外，请参阅 Biophytis 网站上可用的2023年财务报告中的“公司即将面临的风险与不确定性”部分以及20-F表格中的“风险因素”部分以及提交给美国证券交易委员会（SEC）的其他表格。我们没有义务公开更新或审查任何前瞻性声明，无论是因为新的信息，未来的发展还是其他情况，除非法律要求。
Biophytis contacts
Biophytis联系方式
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
投资者关系
Nicolas Fellmann，CFO
Investors@biophytis.com
Media
Antoine Denry:
antoine.denry@taddeo.fr
+33 6 18 07 83 27
媒体
Antoine Denry:
antoine.denry@taddeo.fr
+33 6 18 07 83 27
Nizar Berrada:
nizar.berrada@taddeo.fr
+33 6 38 31 90 50
Nizar Berrada:
nizar.berrada@taddeo.fr
+33 6 38 31 90 50
SOURCE: Biophytis
来源：Biophytis
